StreetInsider.com News Articles

Form DEFA14A Allogene Therapeutics,

Thu, 28 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260528/26568825.html

Form DEFA14A Allogene Therapeutics,

Thu, 28 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260528/26568825.html

Form 8-K Allogene Therapeutics, For: May 28

Thu, 28 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260528/26568780.html

Form 8-K Allogene Therapeutics, For: May 28

Thu, 28 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260528/26568780.html

Allogene Therapeutics announces CEO succession plan

Thu, 28 May 2026 17:06:36 -0400

Allogene Therapeutics Inc. (NASDAQ: ALLO) announced that David Chang will step down as president and chief executive officer effective June 30, 2026, after eight years in the role. Chang will continue serving on the company's board of directors.

The board unanimously elected Zachary Roberts, currently executive vice president of research and development and chief medical officer, to succeed Chang as president and CEO effective July 1, 2026. Roberts will also join the board of directors on the same date.

Chang, one of Allogene's founders, led the South San Francisco-based clinical-stage biotechnology company as it developed allogeneic CAR T products for cancer and

Allogene Therapeutics Announces Planned CEO Succession

Thu, 28 May 2026 17:02:00 -0400

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of Directors
Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief Executive Officer and to the Board of Directors Effective July 1, 2026

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr.

Allogene Therapeutics Announces Planned CEO Succession

Thu, 28 May 2026 17:02:00 -0400

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of Directors
Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief Executive Officer and to the Board of Directors Effective July 1, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Tue, 26 May 2026 08:30:00 -0400

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences.

TD Cowen 7^th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Tuesday, May 26
12:30PM PT/3:30PM ET

Jefferies Global Healthcare Conference, New York
Wednesday, June 3
5:10AM PT/8:10AM ET

H.C. Wainwright 4^th Annual Cell Therapy Virtual Conference
Tuesday, June 9

Any available webcasts will be posted

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Tue, 26 May 2026 08:30:00 -0400

TD Cowen 7^th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Tuesday, May 26
12:30PM PT/3:30PM ET

Jefferies Global Healthcare Conference, New York
Wednesday, June 3
5:10AM PT/8:10AM ET

H.C. Wainwright 4^th Annual Cell Therapy Virtual Conference
Tuesday, June 9

Any available webcasts will be posted

Form DEFA14A Allogene Therapeutics,

Thu, 21 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260521/26530825.html

Form DEFA14A Allogene Therapeutics,

Thu, 21 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260521/26530825.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: CITADEL ADVISORS LLC

Fri, 15 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26507282.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: CITADEL ADVISORS LLC

Fri, 15 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26507282.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Lynx1 Capital Management LP

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506790.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Lynx1 Capital Management LP

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506790.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie

Wed, 13 May 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260513/26487955.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie

Wed, 13 May 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260513/26487955.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Chang David D

Wed, 13 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260513/26487194.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Chang David D

Wed, 13 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260513/26487194.html

Form 10-Q Allogene Therapeutics, For: Mar 31

Wed, 13 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260513/26485881.html

Form 10-Q Allogene Therapeutics, For: Mar 31

Wed, 13 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260513/26485881.html

Form 8-K Allogene Therapeutics, For: May 12

Wed, 13 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260513/26485758.html

Form 8-K Allogene Therapeutics, For: May 12

Wed, 13 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260513/26485758.html

Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 1c

Wed, 13 May 2026 16:02:43 -0400

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Wed, 13 May 2026 16:02:00 -0400

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL)
- 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation Arm
- At Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation Arm
- Favorable Safety Profile with No CRS, ICANS, GvHD, or Treatment-Related Serious Adverse Events or Hospitalizations, Enabling Majority Outpatient Management
- Approximately One-Third of Screening Activity and